Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical (TMCI) to Buy from Neutral with a $16 price target The company has pivoted away from offering solely Lapiplasty, its leading technology ...

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) over the past 12 months. An insider's optimism about the company's prospects is a ...

BTIG analyst Ryan Zimmerman upgraded Treace Medical Concepts (TMCI – Research Report) to a Buy today and set a price target of $16.00. The company’s shares closed yesterday at $9.69.

Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates Lapiplasty ...

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) over the past 12 months. An insider's optimism about the company's prospects is a positive ...

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in ...

Treace Medical Concepts, Inc. has a 1-year low of $3.92 and a 1-year high of $15.98. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51.

(RTTNews) - Treace Medical Concepts, Inc. (TMCI), a leading innovator in medical technologies for bunion and midfoot deformity treatment, announced on Tuesday the successful completion of its ...

PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...